| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027 |
| 10 Nov 2026 | 10-Q |
| 09 Nov 2026 | SCHEDULE 13G/A |
| 30 Oct 2026 | SCHEDULE 13G |
| 21 Oct 2026 |
Form 4: Capers Julien E., See Remarks
Received 787,300 shares as a grant or award |
| 21 Oct 2026 |
Form 3: Capers Julien E., See Remarks
No securities owned |
| 07 Oct 2026 |
Form 4: Jones Mitchell Lawrence, See Remarks
Received 2,620,850 shares by exercise or conversion · Gave up 1,031,102 shares to cover exercise price or tax ($1.54M) |
| 07 Oct 2026 |
Form 4: Finley John David, Director
Received 3,227,384 shares by exercise or conversion · Gave up 1,411,982 shares to cover exercise price or tax ($2.1M) |
| 05 Oct 2026 |
Form 4: Williams Donald Allen, Director
Bought 10,000 shares ($14.2K) · Bought 10,000 shares ($14.6K) |
| 21 Aug 2026 |
Form 4: Finley John David, Director
Gave 88,400 shares as a gift · Acquired 88,400 shares (Gift) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development |
| 29 Jul 2026 | SCHEDULE 13G |
| 10 Jul 2026 |
Form 4: Baltera Robert Jr., Director
Bought 20,000 shares ($39.8K) · Bought 25,000 shares ($48.9K) |
| 08 Jul 2026 |
Form 4: Baltera Robert Jr., Director
Bought 20,000 shares ($41K) · Bought 30,000 shares ($61K) |
| 08 Jul 2026 |
Form 4: Jones Mitchell Lawrence, Chief Medical Officer
Received 131,167 shares by exercise or conversion · Sold 51,880 shares ($107K) |
| 08 Jul 2026 |
Form 4: Finley John David, Director
Received 335,167 shares by exercise or conversion · Sold 146,798 shares ($303K) · Received 133 shares by exercise or conversion ($93.1) |
Loading...